PDCD1 and melanoma: TNF-α and interleukin-2 (IL-2) displayed pro-inflammatory effects and increased T cell trafficking, activation, and proliferation after lysing a mouse melanoma treated with TILT-123, according to Cevera-Carrascon et al. The modified adenovirus, combined with the PD-1 antibody, improved tumor growth control, and OS compared to either single treatment [12].